BRAF and cancer: Consistent with the finding of TCGA project3, we found our PTC tumours harboured a low mutation rate compared to other cancer types, and highly mutated in BRAF gene (16/20 patients, 80%) mainly at its 600 residue (BRAFV600E) (Fig. 2 and Supplementary Data 4).